Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Working memory deficits predict short-term smoking resumption following brief abstinence.

Patterson F, Jepson C, Loughead J, Perkins K, Strasser AA, Siegel S, Frey J, Gur R, Lerman C.

Drug Alcohol Depend. 2010 Jan 1;106(1):61-4. doi: 10.1016/j.drugalcdep.2009.07.020. Epub 2009 Sep 5.

2.

Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers.

Loughead J, Ray R, Wileyto EP, Ruparel K, Sanborn P, Siegel S, Gur RC, Lerman C.

Biol Psychiatry. 2010 Apr 15;67(8):715-21. doi: 10.1016/j.biopsych.2010.01.016. Epub 2010 Mar 6.

PMID:
20207347
3.

Varenicline improves mood and cognition during smoking abstinence.

Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC, Frey JM, Siegel S, Lerman C.

Biol Psychiatry. 2009 Jan 15;65(2):144-9. doi: 10.1016/j.biopsych.2008.08.028. Epub 2008 Oct 8.

4.

Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers.

Ashare RL, McKee SA.

Exp Clin Psychopharmacol. 2012 Feb;20(1):63-70. doi: 10.1037/a0025594. Epub 2011 Sep 26.

5.

A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.

Xenakis JG, Kinter ET, Ishak KJ, Ward AJ, Marton JP, Willke RJ, Davies S, Caro JJ.

Pharmacoeconomics. 2011 Jun;29(6):497-510. doi: 10.2165/11589230-000000000-00000.

PMID:
21452908
6.
7.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD006103.

PMID:
21328282
8.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD006103.

PMID:
21154363
9.

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.

Tonstad S, T√łnnesen P, Hajek P, Williams KE, Billing CB, Reeves KR; Varenicline Phase 3 Study Group..

JAMA. 2006 Jul 5;296(1):64-71.

PMID:
16820548
10.

Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment.

Hajek P, T√łnnesen P, Arteaga C, Russ C, Tonstad S.

Addiction. 2009 Sep;104(9):1597-602. doi: 10.1111/j.1360-0443.2009.02646.x.

PMID:
19686530
11.
12.

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group..

JAMA. 2006 Jul 5;296(1):47-55.

PMID:
16820546
13.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
14.

Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, Wonodi I, Buchanan RW, Myers C, Heishman SJ, Yang J, Nye A.

Arch Gen Psychiatry. 2011 Dec;68(12):1195-206. doi: 10.1001/archgenpsychiatry.2011.83. Epub 2011 Aug 1.

15.

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group..

JAMA. 2006 Jul 5;296(1):56-63. Erratum in: JAMA. 2006 Sep 20;296(11):1355.

PMID:
16820547
16.

Effects of varenicline on abstinence and smoking reward following a programmed lapse.

McClure EA, Vandrey RG, Johnson MW, Stitzer ML.

Nicotine Tob Res. 2013 Jan;15(1):139-48. doi: 10.1093/ntr/nts101. Epub 2012 May 9.

18.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006103. Review. Update in: Cochrane Database Syst Rev. 2008;(3):CD006103.

PMID:
17253581
19.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006103. doi: 10.1002/14651858.CD006103.pub3. Review. Update in: Cochrane Database Syst Rev. 2010;(12):CD006103.

PMID:
18646137
20.

Varenicline's effects on acute smoking behavior and reward and their association with subsequent abstinence.

Perkins KA, Mercincavage M, Fonte CA, Lerman C.

Psychopharmacology (Berl). 2010 May;210(1):45-51. doi: 10.1007/s00213-010-1816-9. Epub 2010 Mar 20.

Supplemental Content

Support Center